Pergolide (administration & dosage) < Pergolide (adverse effects) < Pergolide (chemistry)

Facettes :

List of bibliographic references indexed by Pergolide (adverse effects)

Number of relevant bibliographic references: 23.
[0-20] [0 - 20][0 - 23][20-22][20-40]

Ident.	Authors (with country if any)	Title
002107 (2009)	Andrew H. Evans [Australie] ; James R. Stegeman [Australie]	Punding in patients on dopamine agonists for restless leg syndrome
002416 (2009)	Frank Andersohn [Allemagne] ; Edeltraut Garbe [Allemagne]	Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
002584 (2008)	Kazuo Yamashiro [Japon] ; Miki Komine-Kobayashi [Japon] ; Taku Hatano [Japon] ; Takao Urabe [Japon] ; Hideki Mochizuki [Japon] ; Nobutaka Hattori [Japon] ; Yoshitaka Iwama [Japon] ; Hiroyuki Daida [Japon] ; Michi Sakai [Japon] ; Takeo Nakayama [Japon] ; Yoshikuni Mizuno [Japon]	The frequency of cardiac valvular regurgitation in Parkinson's disease
002D48 (2007)	Gregor Simonis [Allemagne] ; Joerg T. Fuhrmann [Allemagne] ; Ruth H. Strasser [Allemagne]	Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists
003125 (2006)	Ji-Youn Kim [Corée du Sud] ; Eun Joo Chung [Corée du Sud] ; Seung Woo Park [Corée du Sud] ; Won Yong Lee [Corée du Sud]	Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
003347 (2006)	Andrew J. Larner [Royaume-Uni]	Medical hazards of the internet: Gambling in Parkinson's disease
003958 (2005)	Naushad Hirani [Canada] ; Charles C. Bayliff [Canada] ; David G. Mccormack [Canada]	Diagnosis and management of pergolide‐induced fibrosis
003A92 (2004)	K. Ray Chaudhuri [Royaume-Uni] ; Vandena Dhawan [Royaume-Uni] ; Sumit Basu [Royaume-Uni] ; Gordon Jackson [Royaume-Uni] ; Per Odin [Allemagne]	Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non‐ergot agonists may also not be spared
003B13 (2004)	Katherine Grosset [Royaume-Uni] ; Fiona Needleman [Royaume-Uni] ; Graeme Macphee [Royaume-Uni] ; Donald Grosset [Royaume-Uni]	Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five‐drug dose conversion table
003B32 (2004)	Judit Horvath [Suisse] ; Robin D. Fross [États-Unis] ; Galit Kleiner-Fisman [Canada] ; René Lerch [Suisse] ; Hans Stalder [Suisse] ; Suzanne Liaudat [Suisse] ; William J. Raskoff [États-Unis] ; Keith D. Flachsbart [États-Unis] ; Harry Rakowski [Canada] ; Jean-Claude Pache [Suisse] ; Pierre R. Burkhard [Suisse] ; Anthony E. Lang [Canada]	Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
003C40 (2004)	Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]	New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance
003D38 (2004)	Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]	Dopaminagonists and fibrotic valvular heart disease: Further considerations
003D47 (2004)	Pinky Agarwal [États-Unis] ; Stanley Fahn [États-Unis] ; Steven J. Frucht [États-Unis]	Diagnosis and management of pergolide‐induced fibrosis
004114 (2003)	Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni]	Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease
004521 (2002)		DA agonists ‐ Ergot derivaties: Pergolide
004707 (2001)	William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie]	Randomized trial of tolcapone versus pergolide as add‐on to levodopa therapy in Parkinson's disease patients with motor fluctuations
004B08 (2000)	Jaime Kulisevsky [Espagne] ; Carmen García-Sánchez [Espagne] ; Marcelo L. Berthier [Espagne] ; Manel Barbanoj [Espagne] ; Berta Pascual-Sedano [Espagne] ; Alexandre Gironell [Espagne] ; Armando Estévez-González [Espagne]	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients
004C27 (1999)	J. Eric Ahlskog [États-Unis] ; Ryan J. Uitti [États-Unis] ; Michael K. O'Connor [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Joseph Y. Matsumoto [États-Unis] ; Kathy F. Stark [États-Unis] ; Margaret F. Turk [États-Unis] ; Omer L. Burnett [États-Unis]	The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
004E78 (1998)	Juliane Winkelmann [Allemagne] ; Thomas C. Wetter [Allemagne] ; Karen Stiasny [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Claudia Trenkwalder [Allemagne]	Treatment of restless leg syndrome with pergolide—an open clinical trial
005049 (1998)	Hubert H. Fernandez [États-Unis] ; Raymon Durso [États-Unis]	Clozapine for dopaminergic‐induced paraphilias in Parkinson's disease
005638 (1996)	Alicia Facca [États-Unis] ; Juan Sanchez-Ramos [États-Unis]	High‐dose pergolide monotherapy in the treatment of severe levodopa‐induced dyskinesias

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Pergolide (adverse effects)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Pergolide (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Pergolide (adverse effects)
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024